David J. Salant, MD
Boston University School of Medicine
Dept of Medicine

MBBCh, University of the Witwatersrand

Experimental models of immunological glomerular diseases and autoimmunity resembling those seen in man are used to obtain a fundamental understanding of the immunopathogenetic mechanisms of injury.

Antibody-mediated podocyte injury

The primary focus of the Salant laboratory is on the immune basis of glomerular diseases with particular regard to the humoral mechanisms of glomerular cell injury. Current work will elucidate the mechanisms by which antibodies alter the function and morphology of glomerular visceral epithelial cells (podocytes).

1. We have identified the target antigen in human membranous nephropathy as the phospholipase A2 receptor (PLA2R) and shown that about 75% of patients have circulating ant-PLA2R autoantibodies. Current work is directed at defining the mechanisms of podocyte injury induced by anti-PLA2R using a combination of in vitro, in vivo and human genetic techniques. Additional studies will explore the role of anti-PLA2R in the development of recurrent membranous nephropathy post renal transplantation.

2. Ongoing interests include the role of podocyte-specific antibodies, and the effects of complement-mediated injury on podocyte structure, composition of the filtration slit diaphragm and its attachment to the cytoskeleton, and on cell-matrix adhesion using animal models, cell biological and immunochemical methodologies.

Mechanisms of post-inflammatory renal fibrogenesis

We have also developed a murine model of antibody-dependent rapidly progressive glomerulonephritis in which necrotizing and crescentic glomerulonephritis is associated with the activation of chemokine and interstitial-type collagen genes, followed by the development of interstitial fibrosis and renal failure. Since interstitial fibrosis and tubular atrophy are common to all forms of chronic progressive renal diseases and are the most reliable pathological indicators of an adverse long-term prognosis in humans, this mouse model in which the onset of immune injury is rapidly followed (within 5 days) by the induction and proliferation of interstitial cells expressing high levels of mRNA for type I collagen affords a unique opportunity to study the mechanisms of post-inflammatory renal fibrogenesis

Section Chief of Medicine in Nephrology
Boston University School of Medicine

Boston University School of Medicine
Pathology & Laboratory Medicine

Graduate Faculty (Primary Mentor of Grad Students)
Boston University School of Medicine, Division of Graduate Medical Sciences

Active Staff Privileges
Boston Medical Center

2011-2011 International Society of Nephrology: Invited lecture at the World Congress of Nephrology, Vancouver, BC.

Research Training in Nephrology
07/01/1975 - 06/30/2005 (PI)
NIH/National Diabetes & Digestive & Kidney Diseases
5 T32 DK07053 31

Case Mix Models for End Stage Renal Disease Patients
07/31/1996 - 06/30/2001 (Dept Sponsor)
NIH/National Diabetes & Digestive & Kidney Diseases
5 K08 DK02453 05

Research Training in Nephrology
07/01/2015 - 06/30/2020 (PI)

Role of PLA2R and Anti-PLA2R in Idiopathic Membranous Nephropathy
09/01/2011 - 07/31/2017 (PI)

Alnylam Sponsored Research Agreement
05/07/2014 - 05/31/2016 (PI)
Alnylam Pharmaceuticals

Efficacy of Targeted Complement Regulatory Proteins in Experimental Membranous Nephropathy
01/01/2013 - 11/30/2015 (PI)
Alexion Pharmaceuticals

Research Training in Nephrology
07/01/2010 - 06/30/2015 (PI)

Anti-PLA2R Immunoreactivity
05/18/2009 - 05/31/2013 (PI)
Questcor Pharmaceuticals, Inc.

Podocyte-specific human PLA2R transgenic mouse model of membranous nephropathy
07/02/2010 - 06/30/2012 (PI)

Antibody Mediated Glomerular Injury
03/01/2006 - 12/31/2011 (PI)

Research Training in Nephrology
07/01/2005 - 06/30/2010 (PI)

Renal Fibrosis Biotechnology Institute
05/01/2004 - 04/30/2007 (PI)
Serono Reproductive Biotechnology Inst.

Showing 10 of 19 results. Show All Results

Yr Title Project-Sub Proj Pubs
2017 Research Training in Nephrology 5T32DK007053-44 25
2016 Research Training in Nephrology 5T32DK007053-43 25
2015 Role of PLA2R and anti-PLA2R in idiopathic membranous nephropathy 5R01DK090029-05 12
2014 Role of PLA2R and anti-PLA2R in idiopathic membranous nephropathy 5R01DK090029-04 12
2014 Research Training in Nephrology 5T32DK007053-41 25
2014 Research Training in Nephrology 5T32DK007053-41 25
2013 Role of PLA2R and anti-PLA2R in idiopathic membranous nephropathy 5R01DK090029-03 12
2013 Research Training in Nephrology 5T32DK007053-40 25
2012 Role of PLA2R and anti-PLA2R in idiopathic membranous nephropathy 5R01DK090029-02 12
2012 Research Training in Nephrology 5T32DK007053-39 25
Showing 10 of 65 results. Show All Results
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

  1. Larsen CP, Trivin-Avillach C, Coles P, Collins AB, Merchant M, Ma H, Wilkey DW, Ambruzs JM, Messias NC, Cossey LN, Rosales IA, Wooldridge T, Walker PD, Colvin RB, Klein J, Salant DJ, Beck LH. LDL Receptor-Related Protein 2 (Megalin) as a Target Antigen in Human Kidney Anti-Brush Border Antibody Disease. J Am Soc Nephrol. 2018 Feb; 29(2):644-653.View Related Profiles. PMID: 29074737.
  2. Korte EA, Caster DJ, Barati MT, Tan M, Zheng S, Berthier CC, Brosius FC, Vieyra MB, Sheehan RM, Kosiewicz M, Wysoczynski M, Gaffney PM, Salant DJ, McLeish KR, Powell DW. ABIN1 Determines Severity of Glomerulonephritis via Activation of Intrinsic Glomerular Inflammation. Am J Pathol. 2017 Dec; 187(12):2799-2810. PMID: 28935578.
  3. Dai Y, Chen A, Liu R, Gu L, Sharma S, Cai W, Salem F, Salant DJ, Pippin JW, Shankland SJ, Moeller MJ, Ghyselinck NB, Ding X, Chuang PY, Lee K, He JC. Retinoic acid improves nephrotoxic serum-induced glomerulonephritis through activation of podocyte retinoic acid receptor a. Kidney Int. 2017 Dec; 92(6):1444-1457. PMID: 28756872.
  4. Gordon CE, Chitalia VC, Sloan JM, Salant DJ, Coleman DL, Quillen K, Ravid K, Francis JM. Thrombotic Microangiopathy: A Multidisciplinary Team Approach. Am J Kidney Dis. 2017 Nov; 70(5):715-721.View Related Profiles. PMID: 28720207.
  5. Fan X, Yang H, Kumar S, Tumelty KE, Pisarek-Horowitz A, Rasouly HM, Sharma R, Chan S, Tyminski E, Shamashkin M, Belghasem M, Henderson JM, Coyle AJ, Salant DJ, Berasi SP, Lu W. SLIT2/ROBO2 signaling pathway inhibits nonmuscle myosin IIA activity and destabilizes kidney podocyte adhesion. JCI Insight. 2016 Nov 17; 1(19):e86934.View Related Profiles. PMID: 27882344.
  6. Rasouly HM, Kumar S, Chan S, Pisarek-Horowitz A, Sharma R, Xi QJ, Nishizaki Y, Higashi Y, Salant DJ, Maas RL, Lu W. Loss of Zeb2 in mesenchyme-derived nephrons causes primary glomerulocystic disease. Kidney Int. 2016 Dec; 90(6):1262-1273.View Related Profiles. PMID: 27591083; DOI: 10.1016/j.kint.2016.06.037;.
  7. Hoxha E, Beck LH, Wiech T, Tomas NM, Probst C, Mindorf S, Meyer-Schwesinger C, Zahner G, Stahl PR, Schöpper R, Panzer U, Harendza S, Helmchen U, Salant DJ, Stahl RA. An Indirect Immunofluorescence Method Facilitates Detection of Thrombospondin Type 1 Domain-Containing 7A-Specific Antibodies in Membranous Nephropathy. J Am Soc Nephrol. 2017 Feb; 28(2):520-531.View Related Profiles. PMID: 27436855; DOI: 10.1681/ASN.2016010050;.
  8. Haas ME, Levenson AE, Sun X, Liao WH, Rutkowski JM, de Ferranti SD, Schumacher VA, Scherer PE, Salant DJ, Biddinger SB. The Role of Proprotein Convertase Subtilisin/Kexin Type 9 in Nephrotic Syndrome-Associated Hypercholesterolemia. Circulation. 2016 Jul 05; 134(1):61-72. PMID: 27358438; DOI: 10.1161/CIRCULATIONAHA.115.020912;.
  9. Francis JM, Beck LH, Salant DJ. Membranous Nephropathy: A Journey From Bench to Bedside. Am J Kidney Dis. 2016 Jul; 68(1):138-47.View Related Profiles. PMID: 27085376; PMCID: PMC4921260; DOI: 10.1053/j.ajkd.2016.01.030;.
  10. Al-Rabadi L, Ayalon R, Bonegio RG, Ballard JE, Fujii AM, Henderson JM, Salant DJ, Beck LH. Pregnancy in a Patient With Primary Membranous Nephropathy and Circulating Anti-PLA2R Antibodies: A Case Report. Am J Kidney Dis. 2016 May; 67(5):775-8.View Related Profiles. PMID: 26744127; PMCID: PMC4837089; DOI: 10.1053/j.ajkd.2015.10.031;.
Showing 10 of 155 results. Show More

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Bar chart showing 136 publications over 36 distinct years, with a maximum of 8 publications in 1998

Contact for Mentoring:

650 Albany St Evans Biomed Research Ctr
Boston MA 02118
Google Map

Salant's Networks
Click the "See All" links for more information and interactive visualizations
Similar People
Same Department